19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace.

SCAMHC serves all individuals regardless of inability to pay. Discounts for essential services are offered based on family size and income. For more information, contact (334) 222-2523 or our 24/7 Helpline at 1-877-530-0002.



powered by centersite dot net
Child & Adolescent Development: Overview
Basic InformationMore InformationLatest News
Pediatricians Offer Advice on Keeping Trick-or-Treaters SafeThe No. 1 Cause of Halloween Injuries: Carving the PumpkinPfizer Vaccine Prevents 91% of Symptomatic COVID in Young Children: FDAPfizer Says Lower Dose of Its COVID Vaccine Protects Younger ChildrenWhite House Announces COVID Vaccination Plan for Young KidsMany Parents Worry That Kids Fell Behind in Schooling During PandemicNew Device Might Spot 'Lazy Eye' in Kids EarlierA High-Tech Pointer to Pollutants That Trigger Asthma in KidsU.S. Pediatricians, Psychiatrists Declare 'Emergency' in Child Mental HealthState Spending on Poverty Really Pays Off for Kids: StudyNature Helped Many Kids Cope During Lockdown: StudyTwo-Thirds of Parents of Kids Ages 5-11 Plan to Get Them Vaccinated Against COVID: PollKids Can Carry High, Infectious Levels of COVID CoronavirusBystanders Can Make the Difference for a Drowning ChildAs COVID Cases Drop, Fauci Tells Families to Enjoy HalloweenGolf Cart Injuries Keep Rising Among U.S. KidsStudy Confirms Rise in Child Abuse During COVID PandemicSocial Distancing Kept Kids From Getting Flu, RSVPfizer Seeks FDA Emergency Approval for COVID Vaccine in Younger KidsCould an App Help Kids With Severe Ear Condition Avoid Surgery?Kids With Food Allergies Are Often Targets for BulliesAbuse in Childhood May Shorten Adult Lives: StudyAs Kids Turned to Screens During Pandemic, Their Mental Health SufferedRacial Disparities Persist With Childhood Cancers1 in 4 Parents Say Their Kids Have Been Quarantined Since School StartedA Simple Way to Boost Kids' Reading Skills?Sibling Bullying Carries Long-Term Mental Health CostsActive Learning Best for Students: StudyBlack Parents Most Hesitant About COVID Vaccines for Kids: PollPfizer Sends First Data to FDA on COVID Vaccines for Younger KidsWeight Loss Surgery a Good Option for Severely Obese Kids: StudyTough Choices: Chemo That Can Save Kids With Cancer Can Also Damage HearingOver Half of American Children Have Detectable Lead Levels in Their BloodMask Mandates in Schools Curb Infections, CDC Studies ShowPfizer to Ask FDA Soon for Approval of Its COVID Vaccine for Younger ChildrenKeep Your Kids Safe From COVID While Playing SportsNew Tricks to Turn Your Fussy Eater AroundWeight Loss in Childhood May Protect Boys Against Future InfertilityChildhood Trauma Linked With Higher Odds for Adult Neurological IllsParents of Hospitalized Kids Need More Info on Costs: StudyWhich Kids Are at Highest Risk From COVID?Watch Their Backs -- Don't Overload Those SchoolbagsDoctors Often Miss Signs of Type 1 Diabetes in KidsNeighborhood Gun Violence Means Worse Mental Health for KidsLower Dose of Pfizer COVID Vaccine Works Well in Young Children, Company SaysLong-Haul COVID in Kids Typically Ends Within 3 Months: StudyChild Obesity Rose Sharply During PandemicCOVID Vaccines for Kids Under 12 Could Come This Fall: FauciChild Cancers Are Rare, But Here Are Signs to Look ForGetting Kids Eyeglasses Boosts School Grades: Study
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses

Tough Choices: Chemo That Can Save Kids With Cancer Can Also Damage Hearing

HealthDay News
by By Amy Norton HealthDay Reporter
Updated: Sep 28th 2021

new article illustration

TUESDAY, Sept. 28, 2021 (HealthDay News) -- The cancer drug cisplatin can save children's lives, but often with the side effect of hearing loss. Now a new study shows that young children are especially vulnerable, and the hearing damage may begin early in the course of treatment.

The researchers said the findings highlight the need to screen kids' hearing during each round of cisplatin treatment, to catch problems early.

"Cisplatin is the drug of choice for treating solid tumors in children," said Bruce Carleton, senior researcher on the study and director of the Pharmaceutical Outcomes Program at BC Children's Hospital in Vancouver, Canada.

"Solid" tumors are those that form as solid masses, and typically arise in organs (as opposed to the blood or lymph system). Some of the most common in children include cancers of the brain and spinal cord, neuroblastoma (which affects nerve cells) and osteosarcoma (a type of bone cancer).

For them, cisplatin can be life-saving. The problem, Carleton said, is that up to 60% of children treated with the drug develop some degree of hearing loss.

Cisplatin contains platinum, a heavy metal, and research has shown that it can be retained in the cochlea — the part of the inner ear that enables hearing.

In the new study, Carleton's team found that children under 6 years of age were particularly susceptible to developing cisplatin-induced hearing loss over time.

Three years after starting treatment with the drug, 75% of those youngsters had hearing loss. But for many, signs of trouble showed up much sooner: More than one-quarter had hearing problems just three months after starting treatment, the investigators found.

That compared with less than 9% of children aged 6 and older, according to the report published online recently in the journal Cancer.

"This shows that children, even at a very young age, are an important population for hearing loss prevention and intervention," said Kristin Knight, an audiologist at Oregon Health & Science University's (OHSU) Doernbecher Children's Hospital, in Portland.

Knight, who was not involved in the study, said cisplatin typically affects high-frequency hearing, rather than causing full hearing loss. But that is still a major side effect for young children.

"High-frequency speech sounds are critical for spoken language development and understanding, as well as social engagement," Knight said.

She agreed that young children's hearing should be closely monitored during treatment, ideally at each round.

When hearing loss is detected, reducing the cisplatin dose may be an option in some cancers, said Dr. Edward Neuwelt, a professor of neurology at OHSU.

But, he noted, that's only after some hearing damage has occurred.

Researchers are, however, making progress toward preventing the hearing loss in the first place. Neuwelt was senior researcher on a clinical trial of a medication called sodium thiosulfate. It found that the drug reduced hearing loss by almost 50% among children receiving cisplatin for liver cancer.

The drug is now under review by the U.S. Food and Drug Administration for approval. Neuwelt said several other potential preventive treatments are being studied, as well.

Presumably, Carleton said, young children are particularly vulnerable to cisplatin-induced hearing loss because their bodies are smaller and their hearing structures are less mature.

But the precise mechanisms are not clear yet. A better understanding, Carleton said, could lead to more ways to protect children's hearing during cisplatin treatment.

For children who do sustain hearing loss, Knight said there are various ways to intervene. Therapy can help them learn (or relearn) speech, language and listening skills, while some children will also need hearing aids or listening systems. For school-age kids, classroom modifications, like special seating arrangements, can help.

Cisplatin-induced hearing loss is, unfortunately, permanent, Knight said, and it can worsen over time — particularly if a child also received radiation to the head.

More information

St. Jude Children's Research Hospital has more on hearing loss after childhood cancer.

SOURCES: Bruce Carleton, PharmD, director, Pharmaceutical Outcomes Program, British Columbia Children's Hospital, Vancouver, Canada; Kristin Knight, MS, audiologist, Child Development and Rehabilitation Center, Doernbecher Children's Hospital, Oregon Health & Science University, Portland, Ore.; Edward Neuwelt, MD, professor, neurology and neurological surgery, Oregon Health & Science University, Portland, Ore.; Cancer, Sept. 7, 2021, online